| Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study | Cancers |  | | 2023 | 182 | 111 |
|
| Population pharmacokinetics of palbociclib and its correlation with clinical efficacy and safety in patients with advanced breast cancer | Pharmaceutics | | | 2022 | 137 | 238 |
|
